Back to search results

NIRS Monitoring in Premature Infants for Acute Kidney Injury

This study is looking at how oxygen levels in the kidneys of very premature babies (born between 24 and 30 weeks) change over time. Researchers will use a special, non-invasive device called NIRS Monitoring (Near-Infrared Spectroscopy) that measures oxygen saturation in tissues. This device will be placed on your baby within 24 hours of admission. The main goal is to understand these oxygen patterns and to identify factors that might lead to acute kidney injury (AKI), a sudden decrease in kidney function. They will also compare complications like length of hospital stay and time on a breathing machine. Your baby can join if they are less than 30 weeks gestational age and you, as parents/guardians, are willing to sign consent. Babies with known kidney problems are not eligible.

Study design
This is an interventional study planning to enroll 100 premature infants. It is not specified if the study is randomized or blinded.
What's involved
The renal NIRS device will be placed on your baby within 24 hours of admission. The study will measure oxygen levels up to day-of-life 7.
Compensation
Not stated in the trial record.
Follow-up
The primary measurement of average NIRS value (SrSO2) will be taken up to Day-of-life 7.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07222722

NIRS Monitoring in the NICU and AKI

Recruiting
NAAges 24–30InterventionalPrevention
NYU Langone Health
~100 participants
Updated 2025-10-30 on ClinicalTrials.gov
What's tested:NIRS Monitoring

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Average NIRS Value (SrSO2)
Measured over Up to Day-of-life 7

Conditions

Acute Kidney Injury (AKI)
Postnatal AKI

Explore related trials

Acute Renal Failure

Where it's being run

1 sites across 1 states
New York1

Study leadership

  • Sourabh Verma, MD · PRINCIPAL_INVESTIGATOR · NYU Langone Health

Who to contact

Jordan Nelson, MD
[email protected]
3478223664
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Any neonate less than 30 weeks in gestational age
Willingness and capacity of both adult parents/guardians to sign consent

Exclusion

An infant with known congenital anomalies of the kidney (i.e., grade 4 or 5 vesicoureteral reflux (VUR), posterior urethral valves, moderate or severe hydronephrosis, autosomal recessive polycystic kidney disease (ARPKD), bilateral renal agenesis or dysplasia)
Age \>30 weeks gestational age
Age \<24 weeks and \<500 grams (will be excluded due to sensitivity of skin in this vulnerable population).
Clinician's decision that NIRS is not suitable due to the patient's clinical condition

What this trial measures

  • Average NIRS Value (SrSO2)Up to Day-of-life 7

    NIRS values measured as renal tissue oxygen saturation (SrSO2); measured continuously over first 7 days of life.